Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab
Related Experiment Video
Updated: Jun 18, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
S Hakimi1, S Rivière, P Del Giudice
1Service de Médecine Interne A, Centre Hospitalier Universitaire, Montpellier, France. sophie78@netcourrier.com
Abstract:
We report the first case of cutaneous leishmaniasis in a patient treated with infliximab. The species was Leishmania infantum, agent of both cutaneous leishmaniasis and visceral leishmaniasis. Cutaneous leishmaniasis occurred after the 9th infusion of infliximab in a patient who was suffering from ankylosing spondylitis.
Related Concept Videos
Leishmaniasis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiprotozoal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

